Clinical Efficacy of Erdosteine in Patients with Acute or Chronic Bronchitis: A Randomized, Double Blind, Comparative Study vs. Ambroxol.
10.4046/trd.1997.44.6.1296
- Author:
Seok Chan KIM
1
;
Sang Hoak LEE
;
So Hyang SONG
;
Young Kyoon KIM
;
Hwa Sik MOON
;
Jeong Sup SONG
;
Sung Hak PARK
Author Information
1. Department of Internal Medicine, Catholic University Medical College, Seoul, Korea.
- Publication Type:Comparative Study ; Randomized Controlled Trial ; Original Article
- Keywords:
Erdosteine;
Ambroxol;
Bronchitis;
Mucolytics
- MeSH:
Ambroxol*;
Blood Gas Analysis;
Bronchitis;
Bronchitis, Chronic*;
Cough;
Drug-Related Side Effects and Adverse Reactions;
Dyspnea;
Expectorants;
Humans;
Prospective Studies;
Respiratory Function Tests;
Viscosity;
Vital Signs
- From:Tuberculosis and Respiratory Diseases
1997;44(6):1296-1307
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Erdosteine is a thiol derivative developed for the treatement of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. Erdosteine has mucomodulating and antioxidant properties and especially exhibits excellent gastrointestinal tolerability. METHODS: The study was conducted as a prospective evaluation, with 2 comparative groups orally treated with erdosteine 300mg (b.i.d.) or ambroxol 30mg (b.i.d.) for 7 days and the design of trial was double-blind. The treatments have been assigned randomly to patients (n= 80) with acute or chronic bronchitis. The primary end-point used to determine efficacy in this study was subjective symptoms including expectorating frequence, expectoration volume, expectorating difficulty, expectoration viscosity, cough intensity and dyspnea. The secondary end-points of efficacy was the result of arterial blood gas analysis and pulmonary function test. Safety was evaluated with adverse drug reactions and laboratory tests monitoring. 61 patients was included in the efficacy analysis, due to the fact that 19 patients drop-out for different reasons. The obtained values have been analyzed with paired t-test, ANOVA test, multivariate t2-test, repeated measures analysis of covariance, two sample t-test, loglinear-logit model analysis, Fisher's exact test. RESULTS: 1) There was no significant difference on demographic data and vital signs between erdosteine and ambroxol treated groups. 2) The comparison between erdosteine and ambroxol treated groups showed no significant difference in improvement of each symptom in spite of the more favorable efficacy obtained with erdosteine. No difference on the contrary was observed for arterial blood gas analysis and pulmonary function test. 3) As safety is concerned, no clinical significant changes in laboratory test and symptom were induced in erdosteine and ambroxol treated group and two patients in ambroxol treated group drop-out for adverse reactions in symptom. 4) In the evaluation of final clinical efficacy, erdosteine improved more effectively patient's overall symptoms {very good effect (11/31), good effect (12/31), moderate effect (6/31), no effect (2/31), aggravation (0/31)) than ambroxol (very good effect (6/30), good effect (14/30), moderate effect (5/30), no effect (4/30), aggravation (2/30)}. And the probability of symptomatic improvement by erdosteine compared to ambroxol was 2.5 times. (p<0.05). CONCLUISON: This study showed that erdosteine was clinically effective and safe drug for treatment of acute and chronic bronchitis.
